We implemented a protocol incorporating a higher fresh frozen plasma (FFP)/RBC ratio for the management of trauma patients requiring massive transfusion in 2007. This study aims to identify issues that affected the effective deployment of the massive transfusion protocol (MTP) and compare outcome variables with a historic cohort. Data from 49 trauma patients who received at least 10 units of packed RBCs within 24 hours were analyzed and compared with a historic massively transfused cohort who had received recombinant activated factor VII (rFVIIa).
Civilian trauma deaths constitute the leading cause of mortality in young people younger than 45 years. 1 They can be classified as immediate, early, or late. Immediate death occurs due to nonsalvageable injuries such as rupture of the heart and great vessels. 2 Early death happens during the first 6 hours and is typically due to hemorrhage. Early deaths are considered preventable via interventions to prevent exsanguination. This involves rapid control of bleeding via damage-control surgery, selective angiographic embolization, and blood component resuscitation. Late deaths occur after days or weeks and are due to sepsis or organ failure.
The hemostatic system is a balance of procoagulants and anticoagulants. The pathophysiology of coagulopathy in trauma is complex and multifactorial. 3, 4 Acute traumatic coagulopathy leads to hyperfibrinolysis as early as 20 minutes; fibrinolytic activity remains elevated longer in patients with more severe injuries. 4 Other risk factors for coagulopathy include an Injury Severity Score (ISS) of more than 25, a systolic blood pressure of less than 70 mmHg, acidosis with a pH of less than 7.10, and hypothermia with a body temperature of less 3 Mortality reaches 100% when hypothermia occurs in conjunction with acidosis in the presence of bleeding. 5, 6 Dilutional coagulopathy compounds the problem if aggressive crystalloid resuscitation is followed by packed RBCs (PRBCs).
Recombinant activated factor VII (rFVIIa) has been used empirically to treat the coagulopathy of massive transfusion. Tissue factor exposed at the site of endothelial injury complexes with FVIIa to generate thrombin. rFVIIa also enhances factor Xa and factor IXa levels on the surface of activated platelets, adding to the thrombin burst, which leads to a fibrin clot. Since 2004, our institution has had a policy to use low-dose rFVIIa in refractory bleeding after appropriate component therapy in massive transfusion.
Trauma transfusion protocols incorporating higher plasma/PRBC ratios have been derived from military experience in combat casualties. 7 Our facility implemented one such algorithm for the management of trauma patients requiring massive transfusion in 2007. At our blood bank, 4 U of type AB, 4 U of type O, 2 U of type A, and 2 U of type B thawed plasma (with a 5-day expiration date) are available at all times and replenished as necessary.
We undertook a retrospective analysis of the implementation of the massive transfusion protocol (MTP) to document the actual blood component delivery for each activation that occurred and to track timely receipt of a blood bank specimen to permit the use of type-specific components whenever possible. We noticed a dramatic decrease in the request for rescue use of rFVIIa after the implementation of the new MTP protocol. We then compiled a historic cohort of recipients of massive transfusion who had received rFVIIa as rescue therapy after traditional blood component therapy and damage-control surgery or embolization had failed to control hemorrhage.
Materials and Methods
A retrospective analysis was performed to assess the utilization of our MTP. Records of trauma patients for whom the MTP was activated from January 1, 2009, to July 8, 2010, were analyzed. Massive transfusion was defined as receipt of 10 U of PRBCs within 24 hours of admission. Patients with nontraumatic causes of bleeding and patients with traumatic brain injury were excluded from this analysis.
When the MTP is activated by the trauma attending physician, the blood bank is called for the emergency release of the first cooler of 4 U of PRBCs. As soon as the first set of components is issued, a second set consisting of 4 U of PRBCs and 4 U of type AB FFP are prepared for the next pickup. At the same time, the type and screen is performed with subsequent crossmatch of 4 U of typespecific PRBCs and preparation of type-specific plasma. After the second set of blood components, 2 packs of platelets are also prepared. Cryoprecipitate is not routinely included in the algorithm. The decision to activate the MTP is made by the trauma attending physician based on clinical criteria such as proximal limb amputation, hypotension, or coagulopathy on admission.
Our institutional protocol for off-label use of rFVIIa in massive transfusion requires that the trauma team use all standard attempts at hemostasis including surgery and/or angiographic embolization and that patients be normothermic and with pH more than 7.20. Our institutional policy is to use rFVIIa at a low dose of 10 to 20 μg/kg.
The outcome variables analyzed for each cohort of patients include mortality, length of intensive care unit (ICU) stay and number of ventilator days, and 24-hour blood component use. For the purpose of this report, the term "FFP" refers to thawed plasma. Laboratory parameters recorded included international normalized ratio (INR) and PTT values on admission. Data on specific complications including thrombosis, bacteremia/sepsis, and acute lung injury were obtained by searching the trauma registry, the medical record, and pharmacy data (the latter specifically for the use of therapeutic anticoagulation).
While rFVIIa had remained part of the MTP for refractory bleeding, we observed View this table: In this window In a new window that none of the patients in this MTP series required rFVIIa. We retrieved a historic cohort of patients who had received massive transfusions and had received rFVIIa in the 2 years before the implementation of the current MTP.
Statistical analysis was performed using logistic regression and Cox proportional hazards model with SAS software (SAS Institute, Cary, NC).
Results
A total of 49 patients for whom the MTP was activated were trauma patients who received 10 or more units of PRBCs within 24 hours. Demographic data are summarized in Table 1 . The patients were predominantly young males (mean age, 38 years). The proportion of injury by a blunt vs penetrating mechanism was evenly divided. The patients had severe injuries with a mean ISS of 29 and early coagulopathy, as reflected by abnormal coagulation studies on admission (mean INR, 1.5, and PTT, 45 seconds). The hospital mortality rate was 53%, with most deaths occurring within the first 24 hours.
The median FFP/RBC ratio among the entire cohort was 1:1.7. Of the patients, 40 had ratios within the 1:1 to 1:4 range, 3 had more FFP than 1:1, and 6 had less FFP than 1:4. The latter 2 groups were considered outliers. Since our original goal was to approximate a ratio of 1:2, we segregated the 40 cases further into 2 groups of 1:1 to 1:2 and 1:2 to 1:4 ratios to help identify issues that affected the effective deployment of the MTP. For comparison, demographic data, blood component use, and outcome variables were obtained for the historic rFVIIa cohort. Table 1 Demographic Characteristics and Overall Outcome in 49 Trauma Cases * Among the 40 patients who received FFP and RBC within the 1:1 to 1:4 ratio, 28 received a higher ratio of 1:1 to 1:2 and 12 received a lower ratio of 1:2 to 1:4 Table 2 . The number of universal group O PRBCs received by the 1:2 to 1:4 group was slightly higher, but the median total number of PRBCs transfused (16-17 U) was not significantly different for the 2 groups. The 1:1-1:2 group received more aggressive replacement of coagulation factors with plasma, platelets, and, therefore, total components (45 vs 31).
High mortality (92%) was observed in the 1:2-1:4 group; all deaths occurred within 6 hours of admission with a mean of 3.12 hours. Only 1 patient survived to discharge at hospital day 45. The 1:2-1:4 group presented with a much higher mean ISS of 41. In contrast, the 1:1-1:2 group had a mean ISS of 26, inhospital mortality of 25%, and 24-hour mortality of 18%. The mean hospital stay for nonsurvivors was 3.3 days. The mean hospital stay for survivors was 27.3 days with 13.7 ICU days and 8.6 ventilator days. We believe the higher number of blood components received reflects a survival bias in the 1:1-1:2 group.
The historic rFVIIa cohort had a mean ISS of 34 and an in-hospital mortality of 41%, not statistically significant from the referent 1:1-1:2 group. The median FFP/RBC was 1:1.9, but the total number of blood products transfused was much higher than in the current MTP cohort (73 vs 45). Compared with the 1:1-1:2 MTP group, the historic rFVIIa cohort demonstrated a trend toward a longer hospital stay (mean, 29 vs 21 days), more days in ICU (17 vs 14) , and more days on the ventilator (16 vs 9), but these trends did not reach statistical significance.
Logistic regression analysis showed that an ISS of 25 or more is an independent predictor of overall mortality (odds ratio, 9.5; 95% confidence interval [CI], 1.64-54.85). Being in the 1:2-1:4 MTP group compared with the 1:1-1:2 group was associated with increased overall mortality after adjustment for age and ISS (odds ratio, 36; 95% CI, 2.49-508.71). Cox proportional hazards modeling showed that ISS did not predict the length of hospital or ICU stay or duration of ventilator support. Being in the 1:1-1:2 MTP cohort compared with the rFVIIa Complications seen in trauma patients who survive for more than 24 hours include sepsis, thrombosis, and acute lung injury. These complications are shown in Table 3 for the MTP cohort (1:1-1:2 group) and the historic rFVIIa cohort. The lone survivor from the 1:2-1:4 group (data not included in the table), had documented bacteremia with gram-negative rods. The most common organisms isolated in the MTP and rFVIIa survivors were gram-negative rods and coagulase-negative Staphylococcus. There was 1 case of Candida albicans and 1 case of polymicrobial sepsis in the rFVIIa cohort. The incidence of thrombosis was low in both groups and not statistically significant. Acute lung injury is a major concern in trauma patients who receive massive transfusion and aggressive plasma replacement, but the incidence in our MTP series was not statistically different from the historic cohort. The mean duration of ventilator support was actually longer in the rFVIIa cohort than in the MTP 1:1-1:2 cohort (16 vs 9 days).
In Table 4 we list the outlier patients who received greater than 1:1 FFP/RBC resuscitation or less than 1:4 FFP/RBC. The latter group of 6 patients had a median ISS of 25 and died at a median of 3.6 hours after arrival. In 3 of the 6 outlier cases with a low plasma ratio, 5 to 8 plasma units had been issued, but more than half were returned because the patient died.
Discussion
This study examined blood component use in trauma patients after implementation of a new MTP protocol. The major observation is that the majority (63%) of the severely injured patients received component therapy at a ratio of 1:1 to 1:2 FFP/RBC, with low use of type AB plasma and no need for rescue rFVIIa. The MTP patients received significantly fewer total blood components than the historic rFVIIa cohort. MTP was not associated with any increase in lung injury or infectious complications. The patients who received less than the optimal FFP/RBC ratio per our institutional MTP had a much higher ISS and very high mortality. Some studies point to improved prehospital trauma care, which results in more severely injured trauma patients who are transported to hospitals but die shortly after arrival. 8 The nonsurvivors in our study who received a low FFP/RBC ratio died within 3 hours after hospital arrival. Survival bias is introduced as patients who died early were pegged at a low FFP/RBC ratio. 9, 10 Patients who survived longer were able to receive more component therapy. Table 4 Transfusion Data, Clinical Issues, and Outcome of the Outliers * Death due to trauma has a trimodal distribution: early deaths occur within hours and are considered preventable with optimal trauma care to prevent exsanguination. 2, 7 With the improvement in trauma resuscitation, studies have shown a shift in the distribution toward survival from early death. 7 However, there is increased morbidity associated with cellular damage due to ischemia reperfusion injury subsequently resulting in multiple organ dysfunction, such as acute respiratory distress syndrome, renal failure, cardiac dysfunction, infection, and sepsis. 3, 11 Several studies have shown improvement in survival with a high ratio of FFP/RBC resuscitation, starting with combat casualties and later extrapolated to civilian trauma. 7, [12] [13] [14] [15] The relationship between volume of blood loss, reduction of coagulation factors, platelet levels, and the functionality of the hemostatic system is difficult to establish in trauma patients despite mathematical modeling. 16 Routine coagulation studies such as INR and PTT may not reflect ongoing coagulopathy. 3 The body's physiologic response to injury often results in acidosis and hypothermia, and, together with coagulopathy, this triad is a vicious circle and often results in exsanguination. 3, 5, 6 Two important factors in restoring hemostasis are time to coagulation factor replacement and amount replaced. Timely and adequate replacement of coagulation factors results in better control of bleeding in the setting of damage-control surgery. Most trauma hospitals now have institutional algorithms that include fixed FFP/RBC ratios and universal group AB plasma availability. FFP and thawed plasma contain all the coagulation factors, including procoagulants and anticoagulants including antifibrinolytic factors. The optimal FFP/RBC ratio is not known. Although military data suggest 1:1, more recent civilian trauma experience suggests that the optimal ratio is closer to 1:2. 12, 17 Davenport et al 17 reported that the hemostatic effects of FFP may be maximal at ratios of 1:2 in a prospective study quantifying the changes in clot strength by rotational thromboelastography with different ratios. When this ratio is achieved early, it may preempt secondary dilutional coagulopathy and lead to an overall decrease in blood component use, with no increase in the observed incidence of lung injury or nosocomial infection.
rFVIIa induces hemostasis at the site of tissue injury by complexing with exposed tissue factor to activate factor X and enhancing factor Xa production on activated platelets to generate additional thrombin. It obviates the concern for volume overload with large-volume plasma administration and is associated with decreased blood component use and even cost. [18] [19] [20] However, thrombosis is a major complication of rFVIIa use, and there is no proven mortality benefit. 21, 22 Our institutional practice of using low-dose rFVIIa probably accounts for the low baseline incidence of thrombosis in the historic cohort of trauma patients who had received rescue rFVIIa after massive transfusion. 23 Since the institution of an MTP at our institution incorporating a higher FFP/RBC ratio, the use of rFVIIa has decreased tremendously. We estimate that the overall lower blood component utilization and avoidance of rFVIIa use leads to an average cost savings of $13,270 per MTP patient based on blood charges by suppliers, including the technical component 20 Figure 1 . It seems that earlier incorporation of plasma in blood component resuscitation may indeed mitigate trauma-induced coagulopathy, in conjunction with damage-control surgery or embolization. However, with all the limitations imposed by the retrospective nature of our study, there is no evidence that MTP has improved mortality in this subset of severely injured patients.
The limitations of our study are in keeping with those of any small singleinstitution retrospective analysis. These limitations should not discourage trauma centers from examining their empiric practice of adopting new MTPs because trauma demographics and blood component practice and transport within hospitals vary. For instance, our institution has a relatively high proportion of blunt trauma, thawed plasma had been in use for some time before the current MTP, and the blood bank is located in proximity to the operating room. Reliance on type AB plasma should be monitored because it is a scarce resource and because there is an anecdotal association between type AB plasma use and morbidity. 24 Although a recent report suggests that cryoprecipitate may View larger version: In this page In a new window be associated with improved outcomes, 25 our experience suggests that fibrinogen replacement is often adequate with the current MTP (data not shown). The optimal use of cryoprecipitate merits further study before its universal incorporation into an MTP. Finally, the timing of early plasma administration, within the first 6 hours, is critical. 15 We will be prospectively monitoring the exact timing of plasma administration in an ongoing effort to optimize our MTP. Figure 1 Comparison of blood component use and cost between current massive transfusion protocol (MTP) and historic recombinant factor VII (rFVII) cohorts. CRYO, cryoprecipitate; FFP, fresh frozen plasma; PLT, platelets.
